A Free Market Approach to Healthcare: Lower Costs and Better Outcomes

cepr.net· June 24, 2026

A report from the Center for Economic and Policy Research (CEPR) examines the potential for free market strategies to reduce healthcare expenditures while improving patient care quality. The analysis discusses how market-driven competition could influence the pricing and accessibility of medical services and technologies. For the medical device industry, such a shift could lead to significant changes in procurement processes and the competitive landscape for innovative hardware.

Read the full story at cepr.net

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to cepr.net.

More in Medical Devices

Enventric wins Korea Unicorn Bridge, accelerates US and Europe push - CHOSUNBIZ

Enventric wins Korea Unicorn Bridge, accelerates US and Europe push - CHOSUNBIZ Chosunbiz

June 28, 2026

Medical Sales Career Outlook: 2026 Guide Highlights High Earning Potential and Technical Specialization

The medical device and pharmaceutical sales sectors continue to offer high-earning career paths, with median total compensation reaching $161,000 as of mid-2026. This role is critical for the medical device industry as it bridges the gap between complex technical innovations, such as AI-driven machinery, and the clinical professionals who utilize them. Understanding the evolving requirements for education, certification, and specialized technical knowledge is essential for maintaining a robust sales force in an increasingly sophisticated healthcare marketplace.

June 28, 2026

Post-Market Monitoring in Medical Devices

Post-Market Monitoring in Medical Devices Medical Product Outsourcing

June 25, 2026

CMS and FDA Unveil RAPID Pathway to Accelerate Medicare Coverage for Breakthrough Devices

The Centers for Medicare and Medicaid Services (CMS) and the Food and Drug Administration (FDA) have introduced the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway to streamline the transition from regulatory authorization to reimbursement. This initiative specifically targets FDA-designated Class II and Class III breakthrough medical devices, aiming to reduce the coverage gap from over a year to potentially just two months. By aligning evidence requirements early in the development process, the program seeks to ensure that Medicare beneficiaries gain faster access to life-saving and innovative medical technologies.

June 23, 2026